HC Wainwright Has Negative Opinion of SPRB FY2026 Earnings

Spruce Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its FY2026 earnings forecast for Spruce Biosciences to a loss of $29.01 per share from a projected loss of $23.32, while retaining its Buy rating. The current analyst consensus is a loss of $28.15 per share.
  • Spruce reported a quarterly loss of $8.51 per share, missing consensus expectations of a $5.68 loss by $2.83.
  • Analyst sentiment is broadly positive: 11 analysts rate the stock Buy and one rates it Sell, giving it a Moderate Buy consensus and a $158.22 average price target.
  • MarketBeat previews top five stocks to own in December.

Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) - Stock analysts at HC Wainwright decreased their FY2026 earnings estimates for Spruce Biosciences in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($29.01) per share for the year, down from their previous estimate of ($23.32). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Spruce Biosciences' current full-year earnings is ($28.15) per share. HC Wainwright also issued estimates for Spruce Biosciences' Q4 2026 earnings at ($5.71) EPS, Q1 2027 earnings at ($4.35) EPS, Q2 2027 earnings at ($3.96) EPS, Q3 2027 earnings at ($2.58) EPS, Q4 2027 earnings at $0.32 EPS and FY2027 earnings at ($10.38) EPS.

Other equities analysts have also recently issued reports about the company. The Goldman Sachs Group raised Spruce Biosciences to an "overweight" rating in a report on Thursday, August 13th. Weiss Ratings raised Spruce Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, October 6th. Guggenheim reissued a "buy" rating and issued a $104.00 target price (down from $123.00) on shares of Spruce Biosciences in a research report on Monday, August 17th. Citigroup reaffirmed a "market outperform" rating on shares of Spruce Biosciences in a research report on Thursday. Finally, Citizens Jmp set a $143.00 price objective on shares of Spruce Biosciences in a research note on Thursday. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $158.22.

Read Our Latest Stock Analysis on Spruce Biosciences

Spruce Biosciences Trading Down 2.4%

NASDAQ:SPRB opened at $42.25 on Tuesday. The company has a current ratio of 4.83, a quick ratio of 9.23 and a debt-to-equity ratio of 0.06. Spruce Biosciences has a 12 month low of $38.06 and a 12 month high of $127.90. The company has a market cap of $121.43 million, a PE ratio of -1.25 and a beta of 3.57. The company has a 50 day simple moving average of $46.91 and a two-hundred day simple moving average of $54.09.

Spruce Biosciences (NASDAQ:SPRB - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($8.51) EPS for the quarter, missing analysts' consensus estimates of ($5.68) by ($2.83).

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. SkyView Investment Advisors LLC purchased a new stake in Spruce Biosciences in the 2nd quarter worth approximately $162,000. Pale Fire Capital SE purchased a new position in Spruce Biosciences during the second quarter valued at approximately $206,000. AWM Investment Company Inc. bought a new position in shares of Spruce Biosciences in the second quarter worth approximately $7,937,000. Bank of New York Mellon Corp bought a new position in shares of Spruce Biosciences in the second quarter worth approximately $366,000. Finally, Stempoint Capital LP bought a new stake in shares of Spruce Biosciences during the 1st quarter valued at $416,000. Institutional investors own 91.71% of the company's stock.

Spruce Biosciences Company Profile

(Get Free Report)

Spruce Biosciences is a biotechnology company focused on developing treatments for rare endocrine disorders. The U.S.-based company has concentrated on conditions with limited treatment options and has advanced oral drug candidates through clinical development. Its lead investigational candidate, tildacerfont, is a corticotropin-releasing factor type 1 receptor antagonist that Spruce studied for congenital adrenal hyperplasia, a rare disorder affecting hormone production. The company also evaluated the candidate for other endocrine conditions, including polycystic ovary syndrome.

Read More

Earnings History and Estimates for Spruce Biosciences (NASDAQ:SPRB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Spruce Biosciences Right Now?

Before you consider Spruce Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spruce Biosciences wasn't on the list.

While Spruce Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines